Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

Phase 1

Completed

Conditions: Alzheimer Disease
Huntington Disease

Interventions: Drug: digoxin
Drug: dimebon

First Posted Date: 2009-01-29

Last Posted Date: 2009-06-12

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00831506

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

Phase 1

Completed

Conditions: Healthy
Elderly

Interventions: Drug: PF-04447943

First Posted Date: 2009-01-29

Last Posted Date: 2009-06-12

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT00832052

Locations: 🇺🇸
Pfizer Investigational Site, Gainesville, Florida, United States

Tanezumab In Osteoarthritis Of The Knee (2)

Phase 3

Completed

Conditions: Osteoarthritis
Arthritis

Interventions: Biological: tanezumab 5 mg
Biological: tanezumab 10 mg
Other: placebo
Drug: naproxen

First Posted Date: 2009-01-27

Last Posted Date: 2021-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 832

Registration Number: NCT00830063

Locations: 🇺🇸
Anniston Medical Clinic, PC, Anniston, Alabama, United States
🇺🇸
Pinnaccle Research Group, LLC, Anniston, Alabama, United States
🇺🇸
Clinical Research Advantage, Inc. / Mesa Family Medical Center, PC, Mesa, Arizona, United States

and more 89 locations

Open Label Extension In Cancer Patients

Phase 2

Completed

Conditions: Neoplasms
Bone Metastases

First Posted Date: 2009-01-27

Last Posted Date: 2021-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 41

Registration Number: NCT00830180

Locations: 🇺🇸
UCSD Center for Pain Medicine, La Jolla, California, United States
🇺🇸
UCSD Medical Center - Thornton Hospital, La Jolla, California, United States
🇺🇸
UCSD Periman Ambulatory Care Center, La Jolla, California, United States

and more 20 locations

Brain Imaging To Examine The Effect Of Naproxen In Hand Osteoarthritis Patients

Early Phase 1

Completed

Conditions: Osteoarthritis

Interventions: Drug: Placebo
Drug: Naproxen

First Posted Date: 2009-01-27

Last Posted Date: 2011-03-14

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00830050

Locations: 🇬🇧
Pfizer Investigational Site, Denmark Hill, London, United Kingdom

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects

Phase 2

Withdrawn

Conditions: Asthma, Bronchial
Bronchial Diseases
Lung Diseases, Obstructive
Respiratory Tract Diseases

Interventions: Drug: PF - 00610355
Other: Placebo
Drug: PF-00610355

First Posted Date: 2009-01-27

Last Posted Date: 2019-01-31

Lead Sponsor: Pfizer

Registration Number: NCT00830427

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Not Applicable

Completed

Conditions: Solid Tumors

Interventions: Drug: axitinib
Drug: crizotinib

First Posted Date: 2009-01-26

Last Posted Date: 2024-12-03

Lead Sponsor: Pfizer

Target Recruit Count: 52

Registration Number: NCT00828919

Locations: 🇺🇸
UC Irvine Medical Center, Orange, California, United States
🇺🇸
University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

and more 30 locations

Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery

Phase 4

Completed

Conditions: Biliary Tract Surgical Procedures
Pancreaticoduodenectomy
Esophagectomy
Colectomy
Gastrectomy

Interventions: Drug: Tranexamic acid + Standard of Care
Procedure: Standard of Care

First Posted Date: 2009-01-23

Last Posted Date: 2012-04-26

Lead Sponsor: Pfizer

Target Recruit Count: 94

Registration Number: NCT00827931

Locations: 🇮🇳
Pfizer Investigational Site, Surat, Gujarat, India

Relative Bioavailability and Food Effect Study

Phase 1

Withdrawn

Conditions: Pain

Interventions: Drug: PH797804

First Posted Date: 2009-01-22

Last Posted Date: 2015-03-05

Lead Sponsor: Pfizer

Registration Number: NCT00827515

An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis

Phase 2

Completed

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Interventions: Drug: Placebo
Drug: Tanezumab

First Posted Date: 2009-01-22

Last Posted Date: 2021-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 62

Registration Number: NCT00826514

Locations: 🇺🇸
Alabama Research Center, LLC, Birmingham, Alabama, United States
🇺🇸
The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States

and more 39 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy